AbbVie Inc (NYSE: ABBV) saw its stock fall nearly 13% after reporting disappointing mid-stage trial results for emraclidine, ...

Tech megacaps are in the spotlight after Alphabet's quarterly results showed its high-spending push into AI is starting to pay off.

Tech megacaps are in the spotlight after Alphabet's quarterly results showed its high-spending push into AI is starting to ...

Graphics processing units are AI chips used ... to lower-than-anticipated sales of its obesity drugs. Meanwhile, rival AbbVie's stock rose 2% after its earnings topped estimates thanks to sales ...

Graphics processing units are AI chips used in data centers ... expectations due to lower-than-anticipated sales of its ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

Pharmaceutical company AbbVie (ABBV) is the latest stock in my portfolio to announce a higher dividend. Accompanying its third-quarter earnings report, AbbVie declared a 5.8% increase in its ...

The AbbVie Foundation has donated $75 million toward the construction of UChicago Medicine's $815 million freestanding cancer care pavilion in Hyde Park. When the 575,000-square-foot building ...

The AbbVie Foundation, a nonprofit dedicated to addressing health inequities, has made a $75 million donation to the University of Chicago to support the construction of UChicago Medicine’s new cancer ...

AbbVie has inked a deal to work with privately held immuno-oncology company EvolveImmune Therapeutics, to develop therapeutic antibodies for cancer. AbbVie on Thursday said EvolveImmune will ...